Seven scientists will be awarded $600,000 in grants dedicated to osteosarcoma research from MIB Agents, a pediatric osteosarcoma nonprofit. The scientists will be presented their grants at the MIB Agents’ FACTOR Conference in Atlanta, Georgia, this June.
FDA granted full approval of Tecelra (afamitresgene autoleucel) and expanded its indication to include pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.
